1044145-59-6

Basic information

• Product Name: (4-CHLORO-2-METHYLSULFANYL-PYRIMIDIN-5-YL)-METHANOL
• Synonyms: (4-CHLORO-2-METHYLSULFANYL-PYRIMIDIN-5-YL)-METHANOL;(4-chloro-2-(Methylthio)pyriMidin-5-yl)Methanol;4-Chloro-2-(methylthio)-5-pyrimidinemethanol
• CAS NO: 1044145-59-6
• Molecular Formula: C₆H₇ClN₂OS
• Molecular Weight: 191
• Mol File: 1044145-59-6.mol
• Article Data: 17

Chemical Properties

• Boiling Point: 339.6±27.0 °C(Predicted)
• Appearance: /
• Density: 1.45
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: 12.54±0.10(Predicted)
• CAS DataBase Reference: (4-CHLORO-2-METHYLSULFANYL-PYRIMIDIN-5-YL)-METHANOL(CAS DataBase Reference)
• NIST Chemistry Reference: (4-CHLORO-2-METHYLSULFANYL-PYRIMIDIN-5-YL)-METHANOL(1044145-59-6)
• EPA Substance Registry System: (4-CHLORO-2-METHYLSULFANYL-PYRIMIDIN-5-YL)-METHANOL(1044145-59-6)

Safety Data

• Hazardous Substances Data: 1044145-59-6(Hazardous Substances Data)

Usage

General Description

(4-Chloro-2-methylsulfanyl-pyrimidin-5-yl)-methanol is a chemical compound that consists of a pyrimidine ring with a chloro and methylsulfanyl group attached at specific positions. The presence of the chloro and methylsulfanyl group makes this compound useful in various fields such as pharmaceuticals, agrochemicals, and materials science. Its unique structure and properties make it a promising candidate for drug development, as well as for use in crop protection products. Additionally, its ability to modify the properties of materials makes it suitable for use in the production of specialized materials. As a result, (4-Chloro-2-methylsulfanyl-pyrimidin-5-yl)-methanol has the potential to have a significant impact on different industries and applications.

Upstream product

• 5909-24-0 4-chloro-2-methanesulfanylpyrimidine-5-carboxylic acid ethyl ester 

Downstream Products

• 148256-82-0 4-chloro-2-(methylsulfanyl)pyrimidine-5-carboxaldehyde 
• 1192309-52-6 1-{4-Chloro-3-[2-(2-dimethylamino-ethylamino)-8-methoxy-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidin-6-yl]-phenyl}-3-(3-chloro-4-methoxy-phenyl)-urea 
• 1192310-22-7 6-(2-chloro-5-nitrophenyl)-8-methoxy-2-(methylsulfonyl)pyrido[2,3-d]pyrimidin-7(8H)-one 
• 1192310-23-8 6-(2-chloro-5-nitrophenyl)-2-(2-(dimethylamino)ethylamino)-8-methoxypyrido[2,3-d]pyrimidin-7(8H)-one 
• 1192310-18-1 6-(5-amino-2-chlorophenyl)-2-(2-(dimethylamino)ethylamino)-8-methoxypyrido[2,3-d]pyrimidin-7(8H)-one 
• 1192310-28-3 6-(2-chloro-4-nitrophenyl)-8-methoxy-2-(methylsulfonyl)pyrido[2,3-d]pyrimidin-7(8H)-one 
• 1192310-29-4 6-(2-chloro-4-nitrophenyl)-2-(2-(dimethylamino)ethylamino)-8-methoxypyrido[2,3-d]pyrimidin-7(8H)-one 
• 1192310-24-9 6-(4-amino-2-chlorophenyl)-2-(2-(dimethylamino)ethylamino)-8-methoxypyrido[2,3-d]pyrimidin-7(8H)-one 

Relevant articles and documents

Design of Selective PAK1 Inhibitor G-5555: Improving Properties by Employing an Unorthodox Low-pKa Polar Moiety

Signaling pathways intersecting with the p21-activated kinases (PAKs) play important roles in tumorigenesis and cancer progression. By recognizing that the limitations of FRAX1036 (1) were chiefly associated with the highly basic amine it contained, we devised a mitigation strategy to address several issues such as hERG activity. The 5-amino-1,3-dioxanyl moiety was identified as an effective means of reducing pKa and logP simultaneously. When positioned properly within the scaffold, this group conferred several benefits including potency, pharmacokinetics, and selectivity. Mouse xenograft PK/PD studies were carried out using an advanced compound, G-5555 (12), derived from this approach. These studies concluded that dose-dependent pathway modulation was achievable and paves the way for further in vivo investigations of PAK1 function in cancer and other diseases.

Synthetic route of generic FGFR covalent inhibitor PRN1371

The invention relates to a synthetic route of a generic FGFR covalent inhibitor PRN1371, and belongs to the field of medicinal chemistry. The synthetic route steps of the PRN1371 comprise 11 steps, purification of a product can be achieved through simple operation of various intermediates in the aftertreatment process, the problems that the product is difficult to separate, the purification operation yield is low and the like are solved, and industrial production is facilitated. The invention aims to provide a synthetic route of the FGFR irreversible covalent inhibitor PRN1371, and the methodhas the advantages of few synthesis steps, simple operation, high yield, reduction of the production cost, and provision of a new synthesis idea for the industrial production of PRN1371.

BENZODIOXANE DERIVATIVES AND THEIR PHARMACEUTICAL USE

Compounds of formula (I): wherein Ra and Rb are as defined in the claims, exhibit alpha2C antagonistic activity and are thus useful as alpha2C antagonists.